Investigational Gout Drugs Do Well in Clinical Trials
Two major American drug companies are racing to get rival new gout medications to market. Both gout medicines take novel approaches to treating refractory gout - gout that hasn't already responded well to be able to current treatment.
Ardea Biosciences had been the first to announce productive clinical trials of its experimental gout drug RDEA594, also referred to as Lesinurad. Lesinurad's mechanism of action is different from that of the commonly prescribed xanthine oxidase inhibitors gout medications (such as allopurinol and febuxostat), which decrease the development of uric acid.
Lesinurad is often a URAT1 transporter inhibitor which boosts refraining from uric acid with the kidneys. Lesinurad is also active towards another important regulator of urate secretion, OAT4. OAT4 is thought to be responsible for the high uric acid levels in gouty arthritis patients whose condition is caused or worsened by diuretics.
The Lesinurad study involved 208 gout patients who had high blood urate levels for at least A few months, even while taking the gout drug allopurinol. Individuals continued on allopurinol and were randomly assigned to receive either a placebo or lesinurad at doses of 200 mg, 400 mg, or 600 mg for four weeks.
All three groups who were given lesinurad confirmed considerably lower uric acid levels by the end of the month. The percentage of patients who achieved the target for uric acid levels after treatment was 28% in the placebo group, 71% in the 200 mg group, 76% in the 400 mg group, and 87% in the 600 mg group.
More not too long ago, shares of BioCryst Pharmaceuticals rose 12% upon the release of the results of its phase 2b randomized, double-blind, study with the investigational gout drug BCX4208. BCX4208 is often a novel enzyme inhibitor that acts upstream of xanthine oxidase in the purine metabolism path to reduce serum uric acid (sUA).
Its mechanism of action complements xanthine oxidase inhibitors for example allopurinol and also febuxostat in reducing uric acid production, and BCX4208 is intended as an add-on therapy for those gouty arthritis patients who don't respond well to current gout medication.
Like Lesinurad, BCX4208 was studied in gouty arthritis patients who had experienced high blood urate levels for at least 6 months, despite taking the gout drug allopurinol. The 279 study participants were randomly assigned to take BCX4208 at doses of both 5 mg, 10 mg, 20 mg, or 40 mg once daily for 12 weeks. One group of individuals was given a placebo. Just about all participants were also given allopurinal 300 mg once-daily.
- All but one of the doses showed that BCX4208 was superior to the placebo when obtained with allopurinol.
- The BCX4208 doses evaluated in the study showed response rates ranging from 33% in order to 49%, compared to 18% for those taking the placebo.
At this point, Lesinurad appears the more promising of the two gout drugs, and the most likely to hit the market first. It outperformed BCX4208 in early clinical trials, and is farther in advance in the development and approval process. But individual responses to drugs vary, and gout patients will benefit from having two new approaches to reducing the symptoms of this painful condition.
Gout Treatment Natural Gout Symptoms Remedy To Remove Uric Acid Crystals
Gout Treatment http://hydingout.org A gout remedy on how to dissolve & remove uric acid crystals and also to reduce uric acid levels while letting you eat a gout ...
Alex Ray Advocates With Regard to Affordable Access to Healthcare and Medication
She recommends Big Mountain Drugs as the best on the internet Canadian pharmacy from which to buy allopurinol and colchicine for gout. For more information about gout and gout medication, look at the online reference www.colchicine.ca.